New drug combo targets Hard-to-Treat cancers in early trial
NCT ID NCT06789172
First seen Nov 01, 2025 · Last updated May 13, 2026 · Updated 32 times
Summary
This early-phase study tests a new drug called OKN4395, alone or with an immunotherapy (pembrolizumab), in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find safe doses and see if the drug can shrink tumors. About 166 adults will take part across the US, Australia, UK, and EU.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Chris O'Brien Lifehouse
RECRUITINGSydney, New South Wales, Australia
-
Churchill Hospital
RECRUITINGOxford, United Kingdom
-
Leicester Royal Infirmary
RECRUITINGLeicester, LE1 5WW, United Kingdom
-
Linear Clinical Research
RECRUITINGPerth, Western Australia, 6009, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
MD Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
-
Precision NextGen Oncology and Research Center
RECRUITINGBeverly Hills, California, 90212, United States
Contact Phone: •••-•••-••••
-
Sarcoma Oncology Center
RECRUITINGSanta Monica, California, 90403, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
The Beatson
RECRUITINGGlasgow, United Kingdom
-
The Christie
RECRUITINGManchester, United Kingdom
-
University College London Hospital
RECRUITINGLondon, United Kingdom
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.